{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:38:27Z","timestamp":1707525507505},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,14]]},"DOI":"10.7759\/cureus.50541","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T03:55:05Z","timestamp":1702612505000},"source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of Rifabutin-Based Regimens in Treating Helicobacter pylori Infections"],"prefix":"10.7759","author":[{"given":"Jaikirat Singh","family":"Gugnani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fnu","family":"Abhishek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yash","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhiram Rao","family":"Damera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harkamalpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bayan","family":"Taleb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohan","family":"Mane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ujjwal","family":"Soni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kapil D","family":"Nayar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11175216","article-title":"How did we end up using a quadruple guided therapy combining at least two antibiotics with a PPI to eradicate Helicobacter pylori?","volume":"11","author":"Pichon M","year":"2022","unstructured":"Pichon M, Cremniter J, Burucoa C. How did we end up using a quadruple guided therapy combining at least two antibiotics with a PPI to eradicate Helicobacter pylori?. J Clin Med. 2022, 11:5216. 10.3390\/jcm11175216","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8020199","article-title":"Rifabutin-based rescue therapy for Helicobacter pylori eradication: a long-term prospective study in a large cohort of difficult-to-treat patients","volume":"8","author":"Ribaldone DG","year":"2019","unstructured":"Ribaldone DG, Fagoonee S, Astegiano M, et al.. Rifabutin-based rescue therapy for Helicobacter pylori eradication: a long-term prospective study in a large cohort of difficult-to-treat patients. J Clin Med. 2019, 8:199. 10.3390\/jcm8020199","journal-title":"J Clin Med"},{"key":"ref3","unstructured":"List of Bacteria for Which New Antibiotics Are Urgently Needed. (2017). Accessed. November 12, 2022: https:\/\/www.who.int\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21731","article-title":"The global health burden of infection-associated cancers in the year 2002","volume":"118","author":"Parkin DM","year":"2006","unstructured":"Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006, 118:3030-44. 10.1002\/ijc.21731","journal-title":"Int J Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.563","article-title":"ACG clinical guideline: treatment of Helicobacter pylori infection","volume":"112","author":"Chey WD","year":"2017","unstructured":"Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017, 112:212-39. 10.1038\/ajg.2016.563","journal-title":"Am J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.07.007","article-title":"Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions","volume":"155","author":"Savoldi A","year":"2018","unstructured":"Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018, 155:1372-82.e17. 10.1053\/j.gastro.2018.07.007","journal-title":"Gastroenterology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00054-05","article-title":"Pathogenesis of Helicobacter pylori infection","volume":"19","author":"Kusters JG","year":"2006","unstructured":"Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006, 19:449-90. 10.1128\/CMR.00054-05","journal-title":"Clin Microbiol Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2012.00983.x","article-title":"Extragastric manifestations of Helicobacter pylori infection","volume":"17","author":"Bani\u0107 M","year":"2012","unstructured":"Bani\u0107 M, Franceschi F, Babi\u0107 Z, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter. 2012, 17:49-55. 10.1111\/j.1523-5378.2012.00983.x","journal-title":"Helicobacter"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.005348","article-title":"Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review","volume":"94","author":"Arnold DM","year":"2009","unstructured":"Arnold DM, Bernotas A, Nazi I, et al.. Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica. 2009, 94:850-6. 10.3324\/haematol.2008.005348","journal-title":"Haematologica"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13497","article-title":"Review article: the global emergence of Helicobacter pylori antibiotic resistance","volume":"43","author":"Thung I","year":"2016","unstructured":"Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016, 43:514-33. 10.1111\/apt.13497","journal-title":"Aliment Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04887.x","article-title":"Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough","volume":"34","author":"Gisbert JP","year":"2011","unstructured":"Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther. 2011, 34:1255-68. 10.1111\/j.1365-2036.2011.04887.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection - the Maastricht V\/Florence consensus report","volume":"66","author":"Malfertheiner P","year":"2017","unstructured":"Malfertheiner P, Megraud F, O'Morain CA, et al.. Management of Helicobacter pylori infection - the Maastricht V\/Florence consensus report. Gut. 2017, 66:6-30. 10.1136\/gutjnl-2016-312288","journal-title":"Gut"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.01.008","article-title":"Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study","volume":"11","author":"Liang X","year":"2013","unstructured":"Liang X, Xu X, Zheng Q, et al.. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013, 11:802-7.e1. 10.1016\/j.cgh.2013.01.008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10010015","article-title":"Rifabutin for the treatment of Helicobacter pylori infection: a review","volume":"10","author":"Gisbert JP","year":"2020","unstructured":"Gisbert JP. Rifabutin for the treatment of Helicobacter pylori infection: a review. Pathogens. 2020, 10:15. 10.3390\/pathogens10010015","journal-title":"Pathogens"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7326\/M19-3734","article-title":"Rifabutin-based triple therapy (RHB-105) for Helicobacter pylori eradication: a double-blind, randomized, controlled trial","volume":"172","author":"Graham DY","year":"2020","unstructured":"Graham DY, Canaan Y, Maher J, Wiener G, Hulten KG, Kalfus IN. Rifabutin-based triple therapy (RHB-105) for Helicobacter pylori eradication: a double-blind, randomized, controlled trial. Ann Intern Med. 2020, 172:795-802. 10.7326\/M19-3734","journal-title":"Ann Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04937.x","article-title":"Review article: rifabutin in the treatment of refractory Helicobacter pylori infection","volume":"35","author":"Gisbert JP","year":"2012","unstructured":"Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012, 35:209-21. 10.1111\/j.1365-2036.2011.04937.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.02.014","article-title":"Impact of antimicrobial resistance rates on eradication of Helicobacter pylori in a US population","volume":"160","author":"Argueta EA","year":"2021","unstructured":"Argueta EA, Alsamman MA, Moss SF, D'Agata EM. Impact of antimicrobial resistance rates on eradication of Helicobacter pylori in a US population. Gastroenterology. 2021, 160:2181-3.e1. 10.1053\/j.gastro.2021.02.014","journal-title":"Gastroenterology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9351801","article-title":"Rifabutin and furazolidone could be the candidates of the rescue regimen for antibiotic-resistant H. pylori in Korea","volume":"2019","author":"Choi YI","year":"2019","unstructured":"Choi YI, Jeong SH, Chung JW, et al.. Rifabutin and furazolidone could be the candidates of the rescue regimen for antibiotic-resistant H. pylori in Korea. Can J Infect Dis Med Microbiol. 2019, 2019:9351801. 10.1155\/2019\/9351801","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i18.3367","article-title":"Antimicrobial susceptibility testing before first-line treatment for Helicobacter pylori infection in patients with dual or triple antibiotic resistance","volume":"23","author":"Cosme A","year":"2017","unstructured":"Cosme A, Montes M, Ibarra B, et al.. Antimicrobial susceptibility testing before first-line treatment for Helicobacter pylori infection in patients with dual or triple antibiotic resistance. World J Gastroenterol. 2017, 23:3367-73. 10.3748\/wjg.v23.i18.3367","journal-title":"World J Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12900","article-title":"Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen","volume":"27","author":"Inokuchi K","year":"2022","unstructured":"Inokuchi K, Mori H, Matsuzaki J, et al.. Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen. Helicobacter. 2022, 27:e12900. 10.1111\/hel.12900","journal-title":"Helicobacter"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9100685","article-title":"Rifabutin-containing triple therapy (RHB-105) for eradication of Helicobacter pylori: randomized eradicate HP trial","volume":"9","author":"Kalfus IN","year":"2020","unstructured":"Kalfus IN, Graham DY, Riff DS, Panas RM. Rifabutin-containing triple therapy (RHB-105) for eradication of Helicobacter pylori: randomized eradicate HP trial. Antibiotics (Basel). 2020, 9:685. 10.3390\/antibiotics9100685","journal-title":"Antibiotics (Basel)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2021.03.006","article-title":"Multidrug resistance: the clinical dilemma of refractory Helicobacter pylori infection","volume":"54","author":"Kuo CJ","year":"2021","unstructured":"Kuo CJ, Lee CH, Chang ML, et al.. Multidrug resistance: the clinical dilemma of refractory Helicobacter pylori infection. J Microbiol Immunol Infect. 2021, 54:1184-7. 10.1016\/j.jmii.2021.03.006","journal-title":"J Microbiol Immunol Infect"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.780","article-title":"Comparison of eradication rates of moxifloxacin-rifabutin triple therapy and bismuth quadruple therapy as second-line regimens in patients with peptic ulcers","volume":"5","author":"Lee CM","year":"2022","unstructured":"Lee CM, Kim SJ, Hah SI, et al.. Comparison of eradication rates of moxifloxacin-rifabutin triple therapy and bismuth quadruple therapy as second-line regimens in patients with peptic ulcers. Health Sci Rep. 2022, 5:e780. 10.1002\/hsr2.780","journal-title":"Health Sci Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S187063","article-title":"Alternative eradication regimens for Helicobacter pylori infection in Indonesian regions with high metronidazole and levofloxacin resistance","volume":"12","author":"Miftahussurur M","year":"2019","unstructured":"Miftahussurur M, Waskito LA, Syam AF, et al.. Alternative eradication regimens for Helicobacter pylori infection in Indonesian regions with high metronidazole and levofloxacin resistance. Infect Drug Resist. 2019, 12:345-58. 10.2147\/IDR.S187063","journal-title":"Infect Drug Resist"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-019-0482-x","article-title":"Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics","volume":"8","author":"Miftahussurur M","year":"2019","unstructured":"Miftahussurur M, Aftab H, Shrestha PK, et al.. Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics. Antimicrob Resist Infect Control. 2019, 8:40. 10.1186\/s13756-019-0482-x","journal-title":"Antimicrob Resist Infect Control"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213868","article-title":"Five alternative Helicobacter pylori antibiotics to counter high levofloxacin and metronidazole resistance in the Dominican Republic","volume":"14","author":"Miftahussurur M","year":"2019","unstructured":"Miftahussurur M, Cruz M, Doohan D, et al.. Five alternative Helicobacter pylori antibiotics to counter high levofloxacin and metronidazole resistance in the Dominican Republic. PLoS One. 2019, 14:e0213868. 10.1371\/journal.pone.0213868","journal-title":"PLoS One"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1177\/2050640615618043","article-title":"Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: a pilot study","volume":"4","author":"Mori H","year":"2016","unstructured":"Mori H, Suzuki H, Matsuzaki J, et al.. Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: a pilot study. United European Gastroenterol J. 2016, 4:380-7. 10.1177\/2050640615618043","journal-title":"United European Gastroenterol J"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9030121","article-title":"Antibiotic resistance and therapy outcome in H. pylori eradication failure patients","volume":"9","author":"Saracino IM","year":"2020","unstructured":"Saracino IM, Pavoni M, Zullo A, et al.. Antibiotic resistance and therapy outcome in H. pylori eradication failure patients. Antibiotics (Basel). 2020, 9:121. 10.3390\/antibiotics9030121","journal-title":"Antibiotics (Basel)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/1756284819874922","article-title":"Susceptibility-guided therapy for Helicobacter pylori infection treatment failures","volume":"12","author":"Yu L","year":"2019","unstructured":"Yu L, Luo L, Long X, et al.. Susceptibility-guided therapy for Helicobacter pylori infection treatment failures. Therap Adv Gastroenterol. 2019, 12:10.1177\/1756284819874922","journal-title":"Therap Adv Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/185981-effectiveness-of-rifabutin-based-regimens-in-treating-helicobacter-pylori-infections","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:48Z","timestamp":1707509448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/185981-effectiveness-of-rifabutin-based-regimens-in-treating-helicobacter-pylori-infections"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.50541","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,14]]}}}